WaveMan
WaveMan · Company
KYTX · Kyverna Therapeutics, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

KYTX Kyverna Therapeutics (KYTX) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Biological products, (no diagnostic substances) · CIK 0001994702
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
67
13F, latest reported quarter

Kyverna Therapeutics insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for Kyverna Therapeutics, Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
SEIDENBERG BETH C
Director
BUY
2025-12-22 SECtraded 2025-12-18
133,333
$1.0M
-40.7%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 15.3% of the 869,317 shares held after it.
  • 1 other insider bought within 30 days.
  • 67 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director SEIDENBERG BETH C bought about $1,000.0K of KYTX on Dec 18, 2025, the largest insider purchase at the company since 2024; 1 other insider bought within 30 days and 67 funds added in the latest 13F quarter.
Westlake BioPartners Opportunity Fund I, L.P.
BUY
2025-12-22 SECtraded 2025-12-18
133,333
$1.0M
-40.7%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 15.3% of the 869,317 shares held after it.
  • 1 other insider bought within 30 days.
  • 67 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Westlake BioPartners Opportunity Fund I, L.P. bought about $1,000.0K of KYTX on Dec 18, 2025, the largest insider purchase at the company since 2024; 1 other insider bought within 30 days and 67 funds added in the latest 13F quarter.
Walker Karen Marie
Chief Technology Officer
SELL
2025-12-17 SECtraded 2025-12-15
23,998
$292.8K
-24.7%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 106.0% of the 22,636 shares held after it.
  • No other insider sold within 30 days.
  • 67 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Technology Officer Walker Karen Marie sold about $292.8K of KYTX on Dec 15, 2025, the largest insider sale at the company on our record; 67 funds added in the latest 13F quarter.
Vida Ventures GP III, L.L.C.
BUY
2024-02-14 SECtraded 2024-02-12
252,553
$5.6M
-82.3%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 100.0% of the 252,553 shares held after it.
  • 3 other insiders bought within 30 days.
  • 67 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Vida Ventures GP III, L.L.C. bought about $5.6M of KYTX on Feb 12, 2024, the largest insider purchase at the company on our record; 3 other insiders bought within 30 days and 67 funds added in the latest 13F quarter.
Vida Ventures GP III, L.L.C.
BUY
2024-02-14 SECtraded 2024-02-12
583
$12.8K
-82.3%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 100.0% of the 583 shares held after it.
  • 3 other insiders bought within 30 days.
  • 67 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Vida Ventures GP III, L.L.C. bought about $12.8K of KYTX on Feb 12, 2024, the largest insider purchase at the company on our record; 3 other insiders bought within 30 days and 67 funds added in the latest 13F quarter.
8 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 3 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
67 funds bought in last quarter
more than 55% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
26.7% of the float short (float per yahoo 2026-10-26) · 8.8 days to cover · settled 2026-09-30
more than 86% of Pharma & Biotech
The situation: each line is one rule over one dataset
3 clinical trials were terminated, suspended or withdrawn in the last 90 days.
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch KYTX

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-17.7%12M
-18%+13%+45%+76%2025-102025-122026-022026-042026-062026-082026-10 2025-12-18 · SEIDENBERG BETH C bought $1,000.0K2025-12-18 · Westlake BioPartners Opportunity Fund I, L.P. bought $1,000.0K2025-12-15 · Walker Karen Marie sold $292.8K
Insider buyInsider sell
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns KYTX: institutional holders (13F)

13F holdings, latest reported quarter
GordonMD Global Investments LP
4,244,818 sh
$37.8M
GILEAD SCIENCES, INC.
4,126,119 sh
$36.8M
BlackRock, Inc.
3,134,807 sh
$27.9M
Bain Capital Life Sciences Investors, LLC
2,885,000 sh
$25.7M
AIGH Capital Management LLC
2,795,797 sh
$24.9M

Congress trades in KYTX

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

KYTX planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

KYTX mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Simplify Propel Opportunities ETF
$1.6M position · as of 2026-06-30
2.1%
Ultra-Small Company Fund
$997.9K position · as of 2026-06-30
1.0%
WesMark Small Company Fund
$982.8K position · as of 2026-06-30
0.5%
Invesco Dorsey Wright SmallCap Momentum ETF
$1.4M position · as of 2026-05-31
0.3%
Ultra-Small Company Market Fund
$258.4K position · as of 2026-06-30
0.2%
Federated Hermes Prudent Bear Fund
$106.9K position · as of 2026-06-30
0.1%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
7 registered trials, 3 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
2
Phase 2
1 active
1
Not applicable
1 active
4
Multi-phase
1 active
What changed recently
KYSA-3: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in S
2026-09-01 · Active Not Recruiting → Terminated · Study discontinued due to sponsor decision.
PHASE1,PHASE2
KYSA-1: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in S
2026-09-01 · Active Not Recruiting → Terminated · Study discontinued due to sponsor decision.
PHASE1,PHASE2
KYSA-5: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in S
2026-09-01 · Completion moved 2026-03 → 2026-06-16
PHASE1,PHASE2
KYSA-5: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in S
2026-09-01 · Active Not Recruiting → Terminated · Study discontinued due to sponsor decision
PHASE1,PHASE2
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 67 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

KYTX financials

Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Free cash flow, TTM
-$158.8M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
0.15x
long-term debt only, 2026-06-30; equity 2026-06-30
Cash flow to debt
-6.38x
TTM operating cash flow over long-term debt only, 2026-06-30
Return on equity
-87.2%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-68.4%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-82.8%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$319.0M
market value at close 2026-10-26 on 2026-08-03 shares, plus long-term debt only, 2026-06-30, minus cash 2026-06-30
FCF yield
-48.7%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-12
Operating income-$169.8M-$142.6M-$62.4M
Net income-$161.3M-$127.5M-$60.4M
EPS (diluted)-3.64-3.33-89.61
Operating cash flow-$153.7M-$114.2M-$52.4M
Cash$124.1M$96.6M$34.6M
Long-term debt$24.7Mn/an/a
SEC XBRL, fiscal years, as known on 2026-10-28

KYTX Stock Sonar score 4/7 axes

Find similar shapesCompare

KYTX ranks highest on institutional and government (53rd percentile) and financial health (38th), and lowest on risk and compliance (7th), among Pharma & Biotech peers.

Profitability
35
Inputs
  • Return on equity-87.2% · 37 pct, sector of 545
  • Return on assets-68.4% · 35 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-82.8% · 31 pct, sector of 576
Financial health
38
Inputs
  • Debt to equity0.15x · 49 pct, sector of 352
  • Cash flow to debt-6.38x · 27 pct, sector of 371
Institutional and government
53
Inputs
  • Funds adding, latest quarter67 · 55 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quarters$250K · 52 pct, sector of 133
Risk and compliance
7
Inputs
  • Short interest, % of float+26.7% · 7 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
3 not measured: Growth, Insider conviction, US patents
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • Insider conviction needs 1 of 2 inputs, 0 present: no Form 4 purchase or sale (code P or S) in 180 days; no insider trades in 180 days
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies